ALN-HSD

Phase 2Small molecule

ALN-HSD is one of 5 small molecule programs targeting Metabolic Dysfunction-Associated Steatohepatitis (MASH). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 2

1 2

HRS9531

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 2

1 3

Pemvidutide

Altimmune

Phase 3

1 4

CS060380

CCascade Pharmaceuticals, Inc

Phase 2

1 5

ALN-HSD

Alnylam Pharmaceuticals

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT05519475

Clinical

Trials by Indication[1]

Hepatitis1 trial

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Terminated· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 1·NCT04565717·6 enrolled

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors

Recruiting· Regeneron logo

Regeneron·Phase 2·NCT05519475·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALN-HSD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALN-HSD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALN-HSD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alnylam Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Alnylam Pharmaceuticals

ALN-HSD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Hepatitis1 trial

Metabolic Dysfunction-Associated Steatohepatitis (MASH)1 trial

References

Drug Info

Quick Facts

Related News